Albany, NY -- (SBWIRE) -- 11/14/2018 -- A recent report by ResearchMoz.us, titled, "Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy," unearths important information on the trajectory of the market. To that end, it studies the various tailwinds and headwinds to the market and also the current competitive landscape. The report also sheds light on the current and possible size of the Asia Pacific heart failure therapeutics market by examining the sales and revenues.
At the outset, the report states that the Asia Pacific heart failure therapeutics market is likely to rise at a solid 10.1% CAGR over the course of the forecast period starting from 2017 and ending in 2024. The report valued the market at US$733.7 mn in 2017 and projects it to attain a value of US$1,435 mn by 2024.
The report then attempts to find out the reasons that will drive the solid market growth. Foremost among those are changing lifestyles and eating habits leading to stress and obesity, it states. This has created problems of cholesterol, high blood pressure, and diabetes. Apart from that high consumption of tobacco is also leading to various cardiovascular diseases. This, along with a large pool of elderly highly susceptible to various health conditions, are creating opportunities for various heart failure therapeutics in Asia Pacific.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1915182
Having thrown light on the factors fuelling the Asia Pacific heart failure therapeutics market, the report then goes on to add that presence of a plethora of generic, cheap drugs for heart failure is negatively impacting revenue in the market. This is also expected to pose serious challenge to launch of new drugs and therapeutics in the market. Currently, there are a host of them that are in the pipeline.
The report observes that almost half the people having heart failure die in five years' time. This comes down even further with malignancies. The poor long-term prognosis related with HF has generated a need for better the existing therapeutics. Currently, there are several products in the market. Those include ACE inhibitors, ARN-targeted therapy, ATR blockers, MRAs, Beta blockers, diuretics, and ACE inhibitors.
At present, chronic HF-REF patients are mostly being treated with Entresto, ACE inhibitors, Procoralan, beta blockers, and ATR blockers. Similarly, patients having acute HF are being provided with therapeutics such as diuretics, beta blockers, MRAs, and channel inhibitors.
As per the report, Japan is predicted to contribute the most to the Asia Pacific heart failure therapeutics market. Apart from Japan, the report finds China, India, South Korea, and Australia to be other promising markets in the region. The report also finds that licensing deals are a key method of forging strategic alliance in the Asia Pacific heart failure therapeutics market.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG